Incyte (MEX:INCY) Construction In Progress: MXN453 Mil (As of Mar. 2026)


MEX:INCY Incyte Corp MEX:INCY
84 GF Score
Price MXN1,676.03
GF Value MXN1,464.02
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Construction In Progress?

Incyte MEX:INCY 84 Construction In Progress is MXN453 Mil as of Mar. 2026. GuruFocus rates MEX:INCY with a GF Score™ of 84/100 and a GF Value™ of MXN1,464.02 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Incyte's quarterly construction in progress declined from Sep. 2025 (MXN1,279 Mil) to Dec. 2025 (MXN549 Mil) and declined from Dec. 2025 (MXN549 Mil) to Mar. 2026 (MXN453 Mil).

Incyte's annual construction in progress increased from Dec. 2023 (MXN230 Mil) to Dec. 2024 (MXN961 Mil) but then declined from Dec. 2024 (MXN961 Mil) to Dec. 2025 (MXN549 Mil).

Incyte Construction In Progress Historical Data

* Premium members only.

The historical data trend for Incyte's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Construction In Progress Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,514.15 920.68 229.90 960.66 548.90

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,026.51 1,080.82 1,278.70 548.90 453.05
MEX:INCY
84GF Score
Incyte Corp MEX:INCY
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of MXN453 Mil mean?
Incyte (MEX:INCY) has a Construction In Progress of MXN453 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Incyte and its competitors.
Is Incyte's Construction In Progress too high?
Incyte's current Construction In Progress is MXN453 Mil. Overall, Incyte has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Construction In Progress compare to MRNA and ROIV?
Incyte's Construction In Progress of MXN453 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Incyte and its competitors. Incyte's current Construction In Progress is MXN453 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,464.02, compared to a current price of MXN1,676.03 — trading 14.5% above its estimated fair value. The current Construction In Progress is MXN453 Mil. Incyte's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Construction In Progress is MXN453 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN1,676.03 is trading 14.5% above its estimated GF Value™ of MXN1,464.02. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MEX:INCY:

  • Construction In Progress: MXN453 Mil
  • GF Value™: MXN1,464.02 vs. price of MXN1,676.03 (14.5% above fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
84GF Score

Get the complete analysis for MEX:INCY

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,676.03
Price
MXN1,464.02
GF Value